Composition for prophylaxis or treatment of IL-8 related diseases
For example, therapeutic methods and the like for novel IL-8-related diseases using an IL-8 signal inhibitor are provided. Alternatively, for example, therapeutic methods and the like for known or novel IL-8-related diseases using a novel anti-IL-8 antibody are provided.
1. A method for treating an IL-8-related disease, which comprises administering an anti-IL-8 antibody that binds to human IL-8 to a subject in need thereof,
wherein the IL-8-related disease is selected from adenomyosis and post-surgical adhesion; and
wherein the anti-IL-8 antibody comprises:
(a) the amino acid sequence of SEQ ID NO: 23 as HVR-H1,
(b) the amino acid sequence of SEQ ID NO: 29 as HVR-H2,
(c) the amino acid sequence of SEQ ID NO: 30 as HVR-H3,
(d) the amino acid sequence of SEQ ID NO: 26 as HVR-L1,
(e) the amino acid sequence of SEQ ID NO: 31 as HVR-L2, and
(f) the amino acid sequence of SEQ ID NO: 32 as HVR-L3.
2. The method of claim 1 , wherein the anti-IL-8 antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 34 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 35.
3. The method of claim 2 , wherein the anti-IL-8 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 36 and a light chain comprising the amino acid sequence of SEQ ID NO: 38.
4. The method of claim 2 , wherein the anti-IL-8 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 37 and a light chain comprising the amino acid sequence of SEQ ID NO: 38.
5. The method of claim 1 , wherein the disease is adenomyosis.
6. The method of claim 2 , wherein the disease is adenomyosis.
7. The method of claim 3 , wherein the disease is adenomyosis.
8. The method of claim 4 , wherein the disease is adenomyosis.
9. The method of claim 1 , wherein the disease is post-surgical adhesion.
10. The method of claim 2 , wherein the disease is post-surgical adhesion.
11. The method of claim 3 , wherein the disease is post-surgical adhesion.
12. The method of claim 4 , wherein the disease is post-surgical adhesion.